VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

improving the half-life and efficacy of ADCs through strategies like the use of albumin-binding domains or small-format antibodies is an area of active research. Design principles for bispecific ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...

Panelists discuss their perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, ...

Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

The company had completed a phase 1 trial of CDX-585, a bispecific antibody targeting PD-1 and ILT4 in patients with advanced or metastatic solid tumors that had not been halted by standard-of ...

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.

Ideaya plans to submit an investigational new drug application next year for IDE034, a B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate.

improving the half-life and efficacy of ADCs through strategies like the use of albumin-binding domains or small-format antibodies is an area of active research. Design principles for bispecific ...